Irsko - angličtina - HPRA (Health Products Regulatory Authority)

amdipharm limited - clarithromycin - powder for concentrate for solution for infusion - 500 milligram(s) - macrolides; clarithromycin

Spojené státy - angličtina - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole tablets are indicated for the treatment of: prophylaxis: fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. fluconazole is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. there is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. caution should be used in prescribing fluconazole to patients with hypersensitivity to other azoles. coadministration of terfenadine is contraindicated in

Spojené státy - angličtina - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole tablets are indicated for the treatment of: prophylaxis: fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. fluconazole is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. there is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. caution should be used in prescribing fluconazole to patients with hypersensitivity to other azoles. coadministration of terfenadine is contraindicated in

Malta - angličtina - Medicines Authority

neofarma pharmaceuticals limited 42-46, mill street, qormi, qrm 3105, malta - film-coated tablet - clarithromycin 500 mg - antibacterials for systemic use

Malta - angličtina - Medicines Authority

neofarma pharmaceuticals limited 42-46, mill street, qormi, qrm 3105, malta - prolonged-release tablet - clarithromycin 500 mg - antibacterials for systemic use

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - clarithromycin - film-coated tablet - 250 milligram(s) - macrolides; clarithromycin

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - clarithromycin - film-coated tablet - 500 milligram(s) - macrolides; clarithromycin

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - clarithromycin - film-coated tablet - 500 milligram(s) - macrolides; clarithromycin

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - clarithromycin - tablet prolonged release - 500 milligram - clarithromycin

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - clarithromycin - film-coated tablet - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections due to susceptible organisms. such infections include. 1. lower respiratory tract infections (e.g. bronchitis, pneumonia). 2. upper respiratory tract infections (e.g. pharyngitis, sinusitis). 3. skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas). 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 5. is indicated also for the prevention of disseminated mycobacterium avium complex infection in hiv- infected patients with cd4 lymphocyte counts less than or equal to 100/mm3. 6. in the presence of acid suppression is indicated for the eradication of h. pylori, resulting in decreased recurrence of duodenal ulcer.